Primary Sclerosing Cholangitis Market Size (US) among the 7MM, accounting for ~USD 80 Million in 2023, is expected to grow by 2034

DelveInsight's 'Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast - 2034' report delivers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology as well as the market trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.

Discover Key Insights into the Primary Sclerosing Cholangitis Market with DelveInsight's In-Depth Report @ Primary Sclerosing Cholangitis Market Size [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Primary Sclerosing Cholangitis Market Report

* The increase in Primary Sclerosing Cholangitis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Primary Sclerosing Cholangitis Market is anticipated to witness growth at a considerable CAGR.
* The highest diagnosed prevalent cases of Primary Sclerosing Cholangitis were accounted by the US in 2023 (~31 thousand), which are expected to show a rise in the future.
* Among the European countries, Germany had the highest diagnosed prevalent cases of Primary Sclerosing Cholangitis with ~5 thousand cases, followed by the UK in 2023. On the other hand, Spain had the lowest prevalent population (~0.1 thousand cases).
* Japan had ~3 thousand total diagnosed prevalent cases of Primary Sclerosing Cholangitis in 2023, accounting for approximately 5% in 7MM.
* In 2023, in the US, the gender-specific diagnosed prevalent cases of Primary Sclerosing Cholangitis were highest for male (~21 thousand) and female (~10 thousand).
* In 2023, 62% of diagnosed prevalent cases of Primary Sclerosing Cholangitis in Japan were asymptomatic, while 38% were symptomatic.
* The major comorbidity associated with PSC is IBD. As per our estimates, in 2023, ~23 thousand cases belonged to IBD in the US, and is expected to increase during the forecast period.
* The leading Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
* Promising Primary Sclerosing Cholangitis Therapies in the various stages of development include Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.

Stay ahead in the Primary Sclerosing Cholangitis Therapeutics Market with DelveInsight's Strategic Report @ Primary Sclerosing Cholangitis Market Outlook [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Sclerosing Cholangitis Epidemiology Segmentation in the 7MM

* Diagnosed Prevalent Cases
* Gender-specific Diagnosed Prevalent Cases
* Symptoms-specific Diagnosed Prevalent Cases
* Comorbidity (IBD) Specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Primary Sclerosing Cholangitis epidemiology trends @ Primary Sclerosing Cholangitis Prevalence [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Sclerosing Cholangitis Emerging Drugs Profile

* HTD 1801: HighTide Biopharma

HTD1801 is a first-in-class new molecular entity and is an ionic salt of two active moieties - berberine and ursodeoxycholic acid. It is administered orally, acts as a lipid modulator, and significantly reduces liver fat. It has completed a Phase II trial to treat PSC and is currently under Phase II trials for other chronic disorders. The drug has received ODD and FTD. In June 2021, HighTide Therapeutics Inc. announced the topline results of the study of HTD1801 in Primary Sclerosing Cholangitis were presented at the International Liver Congress 2021.

* PLN-74809 (bexotegrast): Pliant Therapeutics, Inc.

PLN-74809 is an oral, small molecule, a dual-selective inhibitor of v6 and v1 being developed to treat PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF- activation, potentially halting the growth of scar tissue. In July 2022, Pliant Therapeutics recieved received FTD from the US FDA for the potential treatment of Primary Sclerosing Cholangitis.

Primary Sclerosing Cholangitis Market Outlook

Management of PSC patients is multimodality based and requires a specialist team with varying skills. The absence of definitive evidence implies that practice is based on expert opinion and local expertise. PSC can be unpredictable; therefore, periodic follow-up in specialist centers is often helpful for patients, as is involvement with support groups. Despite clinical trials of numerous pharmacotherapies over several decades, safe and effective medical therapy remains to be established. Liver transplantation is an option for selected patients with severe complications of PSC, and its outcomes are generally favorable. Treatment is directed toward the specific symptoms that are apparent in each individual and at slowing the progression of the disorder

Get In-Depth Knowledge on Primary Sclerosing Cholangitis Market Trends and Forecasts with DelveInsight @ Primary Sclerosing Cholangitis Treatment Market [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Sclerosing Cholangitis Treatment Market

High-dose ursodeoxycholic acid is used to treat PSC patients because of a trend toward increased survival. Dominant bile duct stenosis should be treated endoscopically. However, liver transplantation remains the only therapeutic option for patients with advanced disease. Apart from this, Immunosuppressive-based therapies such as glucocorticoids, azathioprine, tacrolimus, and a few others are in use, especially in those patients with additional features of autoimmune hepatitis (AIH) or IgG4-related sclerosing cholangitis (IgG4-SC). Although they had shown improvements in liver biochemistry, these effects were not sustained and did not show clinical benefit. The outcomes were not assessed over prolonged periods to determine the progression to cirrhosis. This makes their inclusion in daily practice all the more difficult. Antibiotics, such as vancomycin, metronidazole, and tetracycline, were investigated to assess the interrelationship between systemic and mucosal inflammation. However, limited evidence does not support vancomycin (or other antibiotics) for treating PSC liver disease without cholangitis. Several antimicrobial agents have been used and studied in treating PSC, including rifaximin, tetracycline, minocycline, metronidazole, and OVT, with mixed results.

Major Primary Sclerosing Cholangitis Companies

Several Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.

Unlock Strategic Insights with DelveInsight's Comprehensive Primary Sclerosing Cholangitis Market Report @ Primary Sclerosing Cholangitis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Primary Sclerosing Cholangitis Market Research Report

* Coverage- 7MM
* Study Period- 2020-2034
* Primary Sclerosing Cholangitis Companies- Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
* Primary Sclerosing Cholangitis Pipeline Therapies- Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
* Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis Market Drivers and Barriers
* Primary Sclerosing Cholangitis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Report Introduction

3. Primary Sclerosing Cholangitis (PSC) Market Overview at a Glance

4. Executive Summary of Primary Sclerosing Cholangitis (PSC)

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Patient Journey

8. Emerging Therapies

10. Primary Sclerosing Cholangitis (PSC): 7MM + Nordic Countries Market Analysis

11. SWOT Analysis

12. Unmet Needs

13. KOL Views

14. Market Access and Reimbursement

15. Acronyms and Abbreviations

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-sclerosing-cholangitis-market-size-us-among-the-7mm-accounting-for-usd-80-million-in-2023-is-expected-to-grow-by-2034]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.